Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

100 results about "Interstitial lung disease" patented technology

A group of lung conditions that causes scarring of lung tissues.

Carbon monoxide as a biomarker and therapeutic agent

The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent of heart, lung, liver, spleen, brain, skin and kidney diseases and other conditions and disease states including, for example, asthma, emphysema, bronchitis, adult respiratory distress syndrome, sepsis, cystic fibrosis, pneumonia, interstitial lung diseases, idiopathic pulmonary diseases, other lung diseases including primary pulmonary hypertension, secondary pulmonary hypertension, cancers, including lung, larynx and throat cancer, arthritis, wound healing, Parkinson's disease, Alzheimer's disease, peripheral vascular disease and pulmonary vascular thrombotic diseases such as pulmonary embolism. CO may be used to provide anti-inflammatory relief in patients suffering from oxidative stress and other conditions especially including sepsis and septic shock. In addition, carbon monoxide may be used as a biomarker or therapeutic agent for reducing respiratory distress in lung transplant patients and to reduce or inhibit oxidative stress and inflammation in transplant patients.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Artificial tissue constructs comprising alveolar cells and methods for using the same

The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.
Owner:SANOFI PASTEUR VAX DESIGN

Treprostinil treatment for interstitial lung disease and asthma

The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and / or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates to kits for treatment and / or prevention of such condition that include an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
Owner:UNITED THERAPEUTICS CORP

Carbon monoxide as a biomarker and therapeutic agent

The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent of heart, lung, liver, spleen, brain, skin and kidney diseases and other conditions and disease states including, for example, asthma, emphysema, bronchitis, adult respiratory distress syndrome, sepsis, cystic fibrosis, pneumonia, interstitial lung diseases, idiopathic pulmonary diseases, other lung diseases including primary pulmonary hypertension, secondary pulmonary hypertension, cancers, including lung, larynx and throat cancer, arthritis, wound healing, Parkinson's disease, Alzheimer's disease, peripheral vascular disease and pulmonary vascular thrombotic diseases such as pulmonary embolism. CO may be used to provide anti-inflammatory relief in patients suffering from oxidative stress and other conditions especially including sepsis and septic shock. In addition, carbon monoxide may be used as a biomarker or therapeutic agent for reducing respiratory distress in lung transplant patients and to reduce or inhibit oxidative stress and inflammation in transplant patients.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases

The present invention relates to a novel pharmaceutical composition comprising interferon-γ or pirfenidone and a diagnostic array of candidate polynucleotides for the improved treatment of lung diseases, especially for all forms of interstitial lung diseases. This invention describes the combination of molecular diagnosis and clinical therapy as a novel medication principle for reduction of mortality and improvement of disease management in interstitial lung diseases.
Owner:MONDOBIOTECH LICENSING OUT AG +1

Biomarkers for diagnosis of lung diseases and methods of use thereof

The present disclosure provides methods for diagnosis of interstitial lung diseases (ILDs). The present disclosure provides methods for differential diagnosis of idiopathic pulmonary fibrosis from other ILDs. Compositions and kits useful in carrying out a subject method are also provided.
Owner:VERACYTE INC

Biomarkers for diagnosis of lung diseases and methods of use thereof

The present disclosure provides methods for diagnosis of interstitial lung diseases (ILDs). The present disclosure provides methods for differential diagnosis of idiopathic pulmonary fibrosis from other ILDs. Compositions and kits useful in carrying out a subject method are also provided.
Owner:VERACYTE INC

Interferon gamma polypeptide variants

The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly better utilized. Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variants when administered subcutaneously.
Owner:PERSEID THERAPEUTICS

Amniotic fluid formulation for treatment of lung disorders

InactiveUS20170354692A1Improving exercise enduranceIncreasing baseline blood oxygen saturationDispersion deliveryAntipyreticInterstitial lung diseaseDisease
Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and / or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.
Owner:MAM HLDG OF WEST FLORIDA L L C

Full-length interferon gamma polypeptide variants

The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The full-length interferon gamma polypeptide variants of the invention are useful in therapy, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis.
Owner:PERSEID THERAPEUTICS

Method for predicting and verifying the curative effect of glucocorticoid based on image omics

The invention provides a method for predicting and verifying the curative effect of glucocorticoid based on image omics, which comprises the following steps: S1, acquiring an original medical image ofa patient using glucocorticoid to treat connective tissue disease related interstitial pulmonary disease, and dividing the obtained original medical image into a training group and a verification group; s2, performing quantification processing on the original medical image to obtain image omics feature data; s3, establishing a prediction model of the image omics characteristics in the training group, and performing test verification in the verification group; and step S4, determining effective clinical characteristics and image omics characteristic tags adopting glucocorticoid, and performingverification in a verification group. According to the method, the curative effect of glucocorticoid is predicted and verified on the basis of imaging omics so as to identify patients sensitive to glucocorticoid treatment, and a specific reference basis is provided for doctors to diagnose and treat patients with connective tissue related interstitial pulmonary diseases, so that the patients are effectively treated, and the success rate of treatment is increased.
Owner:THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Biomarkers for lung disease monitoring

The present invention pertains to the monitoring and treatment of lung transplant recipients. In particular, the invention pertains to the use of biomarkers to predict or detect post-lung transplantation complications (e.g., organ rejection, acute organ rejection, organ injury, bronchiolitis obliterans, bronchiolitis obliterans syndrome, organizing pneumonia), fibroproliferative repair responses, interstitial lung diseases (e.g., idiopathic pulmonary fibrosis and other fibrotic lung diseases), and other immune-mediated lung diseases (e.g., graft versus host disease, scleroderma).
Owner:RGT UNIV OF MICHIGAN

Human autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases

In one or more embodiments, the present invention provides a novel biomarker which provides a link between a distinct clinical phenotype and a biochemical effect of an autoantibody on an enzyme implicated in disease pathogenesis. In particular, the present invention provides an isolated or purified human autoantibody to PAD3 protein. Methods of diagnosis of subjects for rheumatoid arthritis (RA) using these antibodies as well as diagnosis of the severity of RA in the subject, and methods for monitoring treatment of a subject with RA are also provided. The biomarkers provided herein are also useful in the diagnosis of connective tissue-interstitial lung disease (CT-ILD) in patients having or suspected of having RA.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Amniotic fluid formulation for treatment of lung disorders

ActiveUS20180140641A1Alleviate or prevent at least one symptom of a lung disorder/injuryReduce inflammationDispersion deliveryAntipyreticInterstitial lung diseaseDisease
Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and / or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.
Owner:MAM HLDG OF WEST FLORIDA L L C

Medicament for treating chronic and intractable lung diseases and preparation method thereof

The invention provides a medicament for treating chronic and intractable lung diseases by acupoint application and summer treatment for winter disease. The medicament is prepared by mixing and grinding white mustard seed, yanhusuo, manchurian wildginger, apricot kernel, processed ephedra herb, common curculigo rhizome and Chinese magnoliavine fruit, and adding fresh ginger juice and honey into the mixture to prepare ointment. The medicament is applied to acupoints in dog days, has definite curative effect of treating winter diseases, has the functions of warming lung and reducing phlegm, nourishing lung and arresting cough, and reinforcing kidney and relieving asthma, and can calm the lung for upper body and reinforce the kidney for the lower body so as to play a role in simultaneously treating principal and subordinate symptoms. By means of the advantages of natural climate, the medicament can fully play the therapeutic effect so as to achieve the effect of getting twice result with half the effort. Clinical effect observation of 86 chronic bronchitis patients, 92 bronchialasthma patients and 102 anaphylacticrhinitis patients proves that the total effective rate of the medicament reaches 91.8 percent, 90.2 percent and 86.2 percent respectively.
Owner:山西省针灸研究所

Xanthine-based cyclic gmp-enhancing rho-kinase inhibitor inhibits physiological activities of lung epithelial cell line

InactiveUS20100317671A1Regulate wound healingInhibit migrationOrganic active ingredientsOrganic chemistryInterstitial lung diseaseAnti-asthmatic drug
A pharmaceutical composition for a treatment of an interstitial lung disease is provided. The pharmaceutical composition comprises an effective amount of an active component being one selected from a group consisting of a KMUP compound, a KMUP monoquaternary ammonium salt and a KMUP monoquaternary ammonium complex salt, wherein the KMUP monoquaternary ammonium complex salt is synthesized by the KMUP compound and a carboxylic acid derivative of one selected from a group consisting of a statin, a non-steroid anti-inflammatory (NSAIDs) and an anti-asthmatic drug.
Owner:KAOHSIUNG MEDICAL UNIVERSITY

Fritillaria superfine powder as well as preparation method and application thereof

The invention discloses fritillaria superfine powder as well as a preparation method and application thereof. The preparation method comprises the following steps: step 1, selecting materials and cleaning; step 2, drying and sterilizing; step 3, grinding and pulping; step 4, pre-freezing slurry; step 5, freezing and drying; step 6, smashing for multiple times into the fritillaria superfine powder with a grain size of 0.5-2 [mu]m. The fritillaria superfine powder is prepared by the preparation method. The fritillaria superfine powder prepared by the preparation method is taken as an only active ingredient to be applied to the preparation of a drug for treating a pulmonary disease. The fritillaria superfine powder disclosed by the invention is used for treating pneumothorax, pulmonary bullous, emphysema, pulmonary shadow, lung cancer, pulmonary heart disease, respiratory failure, pulmonary embolism, pulmonary abscess, pneumonia, neonatal pneumonia, infantile pneumonia, trachitis, asthma, pulmonary tuberculosis, pneumoconiosis and / or interstitial lung disease and has the advantages that the treatment effect is obvious, the condition of a patient is stable, the life quality of the patient is improved, the weight of the patient is increased, the immune function of the patient is improved, and the medication is safe.
Owner:磐安县道地磐药中药研究所

Traditional Chinese medicine preparation for treating connective tissue disease related interstitial lung disease

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine preparation for treating connective tissue disease related interstitial lung disease. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 20-40 parts of radix astragali, 5-20 parts of rhizoma anemarrhenae, 5-20 parts of radix bupleuri, 5-20 parts of rhizoma cimicifugae, 5-15 parts of radix platycodi, 1-10 parts of fructus schisandrae, 10-25 parts of radix salviae miltiorrhizae, 10-20 parts of radix angelicae sinensis and 3-9 parts of radix glycyrrhizae, and further contains 10-20 parts of honeycombs. The traditional Chinese medicine composition can effectively treat the connective tissue disease related interstitial lung disease, and can effectively relieve pulmonary fibrosis.
Owner:THE AFFILIATED HOSPITAL OF SHANDONG UNIV OF TCM

Traditional Chinese medicine composition for treating interstitial lung disease and preparation method of composition

The invention discloses a traditional Chinese medicine composition for treating interstitial lung disease. The traditional Chinese medicine composition comprises the following components according to a certain weight ratio: bamboo leaves, raw gypsum, American ginseng, radix ophiopogonis, lily, dried rehamnnia root, prepared rehmannia root, fritillary bulb, radix scrophulariae, angelica sinensis, radix paeoniae alba, platycodon grandiflorum, rhizoma pinelliae, asparagus cochinchinensis, Chinese yam, radix stemonae, radix glehniae, frost mulberry leaves, chrysanthemum, schisandra chinensis, colla corii asini, cortex lycii radicis, astragalus membranaceus, rhizoma cimicifugae and radix bupleuri. The traditional Chinese medicine composition has the functions of clearing heat and promoting fluid production, boosting qi and nourishing yin, moistening lung and calming the nerves, replenishing and nourishing blood, and can be used for effectively treating interstitial lung disease.
Owner:纪铜镇

Compositions and methods for treatment of lung dysfunction

Described are compositions and methods for the treatment, prevention, or amelioration of a symptom of an airway disorder. In certain aspects, the airway disorder may be one characterized by one or more conditions, such as goblet cell metaplasia, lung tissue inflammation, increased airway hyperresponsiveness, mucus hyperplasia, decreased airway resistance, and increased production of pro-inflammatory cytokines. The compositions and methods may be useful for the treatment of an airway disorder such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), allergic disorders, pulmonary inflammatory diseases, pulmonary fibrosis, and / or interstitial lung diseases.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI

Factor xii inhibitors for treating interstitial lung disease

The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.
Owner:JUSTUS LIEBIG UNIV

Method for acquiring information on condition of patient with interstitial pneumonia and use thereof

The invention relates to a method for acquiring information on a condition of a patient with interstitial pneumonia and application thereof. The present invention addresses the problem of providing ameans capable of identifying the condition of a patient suffering from interstitial pneumonia. The method comprises steps of measuring at least one biomarker in a biological sample of an interstitialpneumonia patient, the biomarker including at least one selected from CXCL9 and CXCL10, a measurement result of the biomarker serving as an index for discrimination between IPAF and CTD-ILD.
Owner:SAPPORO MEDICAL UNIVERSITY +1

Artificial tissue constructs comprising alveolar cells and methods for using the same

The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.
Owner:SANOFI PASTEUR VAX DESIGN

Quinoline derivative or pharmaceutically acceptable salt thereof for combined treatment of interstitial lung disease

The invention discloses a quinoline derivative or a pharmaceutically acceptable salt thereof for combined treatment of interstitial lung diseases. The invention provides application of combination ofa therapeutically effective amount of quinoline compound I or the pharmaceutically acceptable salt thereof and a therapeutically effective amount of second therapeutic drug in preparation of drugs fortreating interstitial lung diseases. The chemical name of the quinoline compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD

Method for treating interstitial lung disease

There is a method of treating or preventing interstitial lung disease in a patient. The method includes the step of administering to the patient a therapeutically effective amount of the compound of the following formula:or a pharmaceutically acceptable salt thereof.
Owner:ALTAVANT SCI GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products